PREPARATION AND EVALUATION OF NILVADIPNE LIQUISOLID COMPACTS
Keywords:
Nilvadipine, PEG, PG, Avicel PH 102, Aerosil, Super disintegrantsAbstract
The purpose of the present study is to develop a novel liquid solid technique which enhances the dissolution rate of water insoluble or poorly water soluble drugs of Nilvadipine, which belong to class II of BCS. Generally the liquisolid technique is based upon the admixture of drug loaded with non volatile solutions (or) liquid drug incorporated with required carrier and coating materials in order to obtain a dry, non adherent, free flowing and compressible powder. Various non volatile solvents used were Propylene glycol, Poly ethylene glycol. The solubility of drug in the non volatile solvents plays an important role in this formulation Avicel PH 102 and aerosil were used as carrier and coating materials. Super disintegrants were used to increase the dissolution rate.Evaluation tests such as Disintegration time, Friability, Hardness and in-vitro dissolution studies were conducted. Amongst all the formulations F14 was considered to be the best in which Propylene glycol is used and the drug release was found to be 97% in 10 min.
Downloads
References
Liquisolid Technology:An Overview. SambasivaRao. A, Naga Aparna. T
Amidon GL, Lennernas H, Shah VP, Crison J R. A theoretical Basis for Biopharmaceutic Drug Classification:the Correlation of in Vitro Drug Product Dissolution and in Vivo Bioavailability. J Pharm Res 1995;12:413-20.
Hiremath SN, Raghavendra RK, Sunil F, Danki LS, Rampure MV, Swamy PV, Bhosale UV. Dissolution enhancement of gliclazide by preparation of inclusion complexes with β-cyclodextrin. Asian J Pharm 2008;2:73-6.
Kornblum S, Hirschorn J. Dissolution of poorly watersoluble drugs I:Some physical parameters related to method of micronization and tablet manufacture of a quinazolinone compound. J Pharm Sci 1970;59:607-09.
Venkateskumar K, Arunkumar N, VermaPriyaRanjan PB, Siva P, Neema G, Punitha K, Characterization of Olanzapine-Solid Dispersions. Iranian J of Pharmaceutical Res 2011;10 (1):13-24.
Nikhil K, Sachan, SeemaPushkar, S S Solanki, Dagendra S Bhatere. Enhancement of Solubility of Acyclovir by Solid Dispersion and Inclusion Complexation methods.
Sekiguchi K, Obi N. Studies on absorption of eutectic mixtures. I. A comparison of the behavior of eutectic mixtures of sulphathiazole and that of ordinary sulphathiazole in man. J Chem Pharm Bull 1961;9:866-72.
Sharma D K, Joshi S B. Solubility enhancement strategies for poorly waterâ€soluble drugs in solid dispersions:A Review. Asian J Pharmaceutics 2007;1(1):9-19.
Banga S, Chawla G, Bansal A K. New Trends in the Crystallisation of Active Pharmaceutical Ingredients, Businessbriefing. J Pharmagenerics 2004;70-74.
Venkateskumar K, Arunkumar N, VermaPriya R P, Siva P, Neema Gand Punitha K, Characterization of Olanzapine-Solid Dispersions. Iranian J of Pharmaceutical Res 2011;10 (1):13-24.
Y. Javadzadeh, B. Jafari-Navipour, A. Nokhodchi, Liquisolid technique for dissolution rate enhancement of a high dose water-insoluble drug carbamazepineâ€. Int J of Pharmaceutics 2007:341(1-2):26-34.
Liquisolid systems and methods of preparing same.US 5968550 A
Spireas S, Sadu S. Enhancement of prednisolone dissolution properties using liquisolid compacts. Int J Pharm 1998;166:177-88.
Sirisha, B. Sruthi, M. Namrata, I. BhavaniHarika, P.Kirankumar, A Review on Liquid Solid Compacts V.N.L.
Yousefjavadzadeh, Mohammad Reza, SiahiSolmaz, Asnaashari, Alinokhodchi. Liquisolid technique as a tool for enhancement of poorly water-soluble drugs and evaluation of their physicochemical properties. J Acta Pharm 2007;57:99-109.
Indian Pharmacopoeia, 4th Edn., Vol. II:Controller of Publications, Govt. of India, Ministry of Health & Family Welfare, New Delhi;1996:735.
Mehta RM. Pharmaceutics-I, VallabhPrakashan, 2nd edn;1997.
Indian Pharmacopoeia, Ministry of Health and family welfare, Government of India, Vol 2, Published by the controller of publications, Delhi. 1996, A-8.
The United States Pharmacopoeia National Formulary, USP28 NF23. The United States Pharmacopoeial Convention, Canada. 2005, 342-34